Fibrodysplasia ossificans progressiva disorder builds a second skeleton

Imagine a bruise that never heals — instead, it hardens into bone. A small swelling that doesn’t fade but permanently locks a ...
Seeking Alpha

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective ...

FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority ...

Quotient and Ipsen extend partnership for ultra-rare disease therapy

The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, ...
MPR

Garetosmab Granted Priority Review for Fibrodysplasia Ossificans Progressiva

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.

Regeneron Gets Speedy FDA Review of Garetosmab in FOP

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of garetosmab for adults with the ultra-rare genetic disorder fibrodysplasia ...